Current Directions in Radiopharmaceutical Research and Development

  • Stephen J. Mather

Part of the Developments in Nuclear Medicine book series (DNUM, volume 30)

Table of contents

  1. Front Matter
    Pages i-xvi
  2. Jonathan R. Dilworth, Suzanne J. Parrott
    Pages 1-29
  3. Alfons M. Verbruggen
    Pages 31-46
  4. Suresh C. Srivastava
    Pages 63-79
  5. Colin M. Archer, Barbara Edwards, Nigel A. Powell
    Pages 81-88
  6. Lorna M. D. Stewart
    Pages 89-98
  7. Leonard I. Wiebe
    Pages 115-135
  8. Michael J. Welch, Joanna B. Downer, John A. Katzenellenbogen
    Pages 137-156
  9. Donald J. Hnatowich
    Pages 157-168
  10. Anthony P. Davenport, Fraser D. Russell
    Pages 169-179
  11. David Barlow
    Pages 181-199
  12. Philip J. Blower
    Pages 219-232
  13. Back Matter
    Pages 233-240

About this book


Radiophannaceutical research has recently undergone a major change in direction. In past years it has been concerned mainly with the development of perfusion tracers, the biodistribution of which reflect the regional blood flow to areas of major organs such as the heart and brain. However, a major new direction of interest now lies in the development of receptor-binding radio-tracers which can be used to perform in-vivo characterisation of diseased tissues and it is likely that much of the future research in this field will follow this direction. The difficulties in developing such tracers are considerable. The researcher must first identify a promising target for radiopharmaceutical development. High specific activity radioactive molecules must be designed and synthesised which will both bind to the target receptor with high affinity, and also have the physicochemical characteristics which will allow them to reach the target site in sufficient quantity while at the same time showing minimal uptake in non-target tissues. Thus the knowledge base required for radiophannaceutical development has now expanded beyond the limits of radiopharmaceutical chemistry to include aspects of biochemistry, molecular biology and conventional drug design. The portfolio of basic knowledge required to support current radiopharmaceutical development is changing and scientists working in this arena need to be trained in this regard. At the same time, the very latest developments in the field need to be communicated to the scientific community in order to stimulate the advancement of this exciting new direction of research.


CNS cell chemistry computer diagnostic imaging hormones imaging positron emission tomography (PET) research

Editors and affiliations

  • Stephen J. Mather
    • 1
  1. 1.Department of Nuclear Medicine, Imperial Cancer Research FundSt. Bartholomew’s HospitalLondonUK

Bibliographic information

  • DOI
  • Copyright Information Springer Science+Business Media B.V. 1996
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-010-7289-2
  • Online ISBN 978-94-009-1768-2
  • Buy this book on publisher's site